Greenwood Capital Associates LLC Buys Shares of 2,349 United Therapeutics Co. (NASDAQ:UTHR)

Greenwood Capital Associates LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,349 shares of the biotechnology company's stock, valued at approximately $724,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cerity Partners LLC boosted its stake in shares of United Therapeutics by 30.4% during the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $4,098,000 after buying an additional 2,702 shares during the last quarter. Korea Investment CORP grew its stake in United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Illumine Investment Management LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $3,015,000. Nepsis Inc. increased its position in shares of United Therapeutics by 6.7% during the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock worth $18,057,000 after purchasing an additional 3,653 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $1,899,000. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Price Performance

United Therapeutics stock traded down $2.79 during midday trading on Friday, hitting $283.35. The company's stock had a trading volume of 564,424 shares, compared to its average volume of 452,608. The company has a market cap of $12.78 billion, a price-to-earnings ratio of 12.44, a PEG ratio of 0.97 and a beta of 0.57. The company has a 50-day moving average price of $300.43 and a two-hundred day moving average price of $331.51. United Therapeutics Co. has a 1-year low of $266.98 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the company posted $6.17 earnings per share. Sell-side analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Analyst Ratings Changes

UTHR has been the subject of several analyst reports. Morgan Stanley raised their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Cantor Fitzgerald initiated coverage on United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective on the stock. Bank of America dropped their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Finally, HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $393.08.

Insider Buying and Selling

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the transaction, the chief financial officer now owns 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,500 shares of company stock worth $20,828,390. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.